Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Vioxx Documents Offer Case Study For “Drug Watch” Website

Executive Summary

The discussions between Merck and FDA regarding the best way to present safety data from the VIGOR trial in Vioxx labeling offer a case study in how the agency's new "Drug Watch" safety website may affect disclosure of risk information

You may also be interested in...

FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system

Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?

The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts